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Abstract 
Background: The Plasmodium falciparum reticulocyte binding protein homolog 2b (PfRh2b) is an important P. falci-
parum merozoite ligand that mediates invasion of erythrocytes by interacting with a chymotrypsin‑sensitive “receptor 
Z”. A large deletion polymorphism is found in the c‑terminal ectodomain of this protein in many countries around the 
world, resulting in a truncated, but expressed protein. The varying frequencies by region suggest that there could be 
region specific immune selection at this locus. Therefore, this study was designed to determine temporal changes in 
the PfRh2b deletion polymorphism in infected individuals from Thiès (Senegal) and Western Gambia (The Gambia). 
It was also sought to determine the selective pressures acting at this locus and whether prevalence of the deletion 
in isolates genotyped by a 24‑SNP molecular barcode is linked to background genotype or whether there might be 
independent selection acting at this locus.
Methods: Infected blood samples were sourced from archives of previous studies conducted between 2007 and 
2013 at SLAP clinic in Thiès and from 1984 to 2013 in Western Gambia by MRC Unit at LSHTM, The Gambia. A total of 
1380 samples were screened for the dimorphic alleles of the PfRh2b using semi‑nested Polymerase Chain Reaction 
PCR. Samples from Thiès were previously barcoded.
Results: In Thiès, a consistent trend of decreasing prevalence of the PfRh2b deletion over time was observed: from 
66.54% in 2007 and to 38.1% in 2013. In contrast, in Western Gambia, the frequency of the deletion fluctuated over 
time; it increased between 1984 and 2005 from (58.04%) to (69.33%) and decreased to 47.47% in 2007. Between 2007 
and 2012, the prevalence of this deletion increased significantly from 47.47 to 83.02% and finally declined significantly 
to 57.94% in 2013. Association between the presence of this deletion and age was found in Thiès, however, not in 
Western Gambia. For the majority of isolates, the PfRh2b alleles could be tracked with specific 24‑SNP barcoded geno‑
type, indicating a lack of independent selection at this locus.
Conclusion: PfRh2b deletion was found in the two countries with varying prevalence during the study period. How‑
ever, these temporal and spatial variations could be an obstacle to the implementation of this protein as a potential 
vaccine candidate.
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Background
Despite significant efforts and progress directed towards 
malaria prevention and control, malaria from Plasmo-
dium falciparum parasite infection remains a major 
global health challenge. This is due to multiple factors, 
including insecticide resistance in anopheline vectors, 
the emergence and rapid spread of drug-resistant para-
site strains and especially the lack of an effective vaccine. 
Fig. 1 Evolution of PfRh2b deletion in Thiès (a) and Western Gambia (b). Scheme showing the variation in the prevalence of PfRh2b deletion over 
the time, including mixed infections (PfRh2 full‑length and PfRh2b deletion) in both areas using formula described previously by Ahouidi et al. [10]. 
Alleles frequencies of the dimorphic PfRh2b gene were determined using semi‑nested Polymerase Chain Reaction (PCR). a A decrease of PfRh2b 
deletion from 2007 to 2013 in Thiès was noted. b A fluctuation of this deletion from 1984 to 2013 in The Gambia was observed. N, number of 
isolates; Del, deletion
Page 3 of 11Diédhiou et al. Malar J          (2019) 18:239 
Therefore, the development of an effective malaria vac-
cine remains critical for malaria eradication. However, 
efforts at developing a malaria vaccine have been ham-
pered by the extensive genetic diversity in malaria para-
site populations and allele specific immunity in endemic 
human populations [1, 2].
Characterization of genetic polymorphisms in key 
vaccine antigens of P. falciparum will enable a better 
understanding of the molecular evolution of parasite 
populations that could affect efficacy of future vaccines 
[3]. Plasmodium falciparum Reticulocyte binding protein 
homologues (PfRhs) are expressed at the apical surface of 
invasive merozoite [4–7] and are believed to play a role 
in the recognition of the erythrocyte and in tight junc-
tion formation [8]. Towards design of a vaccine, several 
studies are looking at the immunity and diversity of the 
PfRh family of proteins [6, 8–13]. There are five func-
tional PfRh genes: P. falciparum Reticulocyte-binding 
protein homolog 1 (PfRh1) [14, 15], PfRh2a, PfRh2b 
[16–18], PfRh4 [19, 20], and PfRh5 [21–23]. Two mem-
bers of the P. falciparum Rh ligands, PfRh2a and PfRh2b, 
are important mediators of parasite invasion. PfRh2b 
mediates invasion by interacting with a chymotrypsin-
sensitive erythrocyte receptor Z [24]. These proteins are 
currently being assessed as invasion-blocking vaccine 
candidates [11, 25]. However, they differ structurally at 
the c-terminal.
The c-terminal region of PfRh2b gene presents a large 
structural polymorphism (0.58 kb) and this was found at 
high frequencies in field isolates from different areas of 
Africa [10, 26, 27]. The prevalence of this deletion was 
characterized for the first time in 2006 in parasite popu-
lations from different areas [10]. However, the prevalence 
and evolution of the PfRh2b protein as malaria declines 
remains unknown. Understanding the changes over time 
in the frequencies of allelic variants in potential vac-
cine candidate will be important, as these changes could 
affect the efficacy of a candidate vaccine. Therefore, it is 
important to assess temporal changes in the PfRh2b gene 
and prevalence of the dimorphic alleles PfRh2b deletion 
(PfRh2bdel) over time in endemic populations.
As shown for Thiès, in Senegal, neutral single nucleo-
tide polymorphism (SNP) markers can sensitively deter-
mine temporal changes in P. falciparum genotypic 
diversity [28]. There are extensive hotspots of diversity 
across the genome, mostly within genes exposed on 
the surface of the parasite and erythrocyte, including 
invasion ligands. These ligands are a target of immune 
responses and remain a major focus for development of a 
blood stage vaccine [29, 30].
As the frequency of genotypes changes as well as the 
PfRh2b alleles, the prevalence of the deletion was deter-
mined using molecular barcode to examine whether 
allelic frequencies are strictly related to barcode hap-
lotype clusters or independent selection at the PfRh2b 
locus could be driving frequencies in the population. 
This provides data relevant for further consideration of 
PfRh2b and other structurally variant proteins as targets 
for vaccine development.
Methods
Study sites and Plasmodium falciparum field isolates
Archived P. falciparum DNA samples from infected 
blood samples of consenting individuals were sourced 
from previous studies conducted between 2007 and 2013 
at the Service de Lutte Anti-Parasitaire (SLAP) clinic in 
Fig. 2 Percentage of PfRh2b deletion according to age groups 
in Thiès (a) and Western Gambia (b). Variation in the presence of 
PfRh2b deletion according to age of patients from two distinct 
populations. a In Thiès, the median age of the 651 Patients was 
18 years. A significant difference in the presence of PfRh2b deletion 
was observed (P = 0,037). b In Western Gambia, the median age of 
the 283 Patients was 5 years. No difference in the presence of PfRh2b 
deletion was found (P = 0.316). P, P value; ns, not significant; Del, 
deletion
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Thiès (70 km from Dakar, the capital city of Senegal) and 
from 1984 to 2013 in Western Gambia. Overall, malaria 
prevalence is moderate in The Gambia with high seasonal 
transmission [31, 32]. In contrast, Thiès is characterized 
by a perennial hypo-endemic transmission. These stud-
ies had received ethical approval from the Institutional 
Review Boards of the Harvard School of Public Health, 
the Ethics Committee of the Ministry of Health in Sen-
egal and the Joint Gambian Government/MRCG Eth-
ics Committee. A total of 1380 (849 from Thiès and 531 
from Western Gambia) P. falciparum malaria infected 
blood samples were analysed. Among the Thiès samples, 
580 that has been previously genotyped using a molecu-
lar barcode of 24 SNPs by Daniels et  al. [33] were used 
for determining the association between alleles of PfRh2b 
and the specific barcode of parasite.
PfRh2b genotyping
Semi-nested PCR method, as described previously [10], 
was used to amplify an PfRh2b gene fragment including 
the deletion in all extracted DNA samples. A positive 
control (P. falciparum laboratory cloned line 3D7) and 
negative control (reagent grade water) were included in 
all PCR amplifications. The size of the PCR products was 
estimated using Gene Ruler 100 bp DNA ladder marker 
(Quick  Load®, 100pb DNA Ladder).
Statistical analysis
For continuous variables median and interquartile range 
were calculated, while for categorical variables, the 
proportion or prevalence of the outcome with 95% CI 
was calculated.
For each year, to take into account the prevalence in 
mixed genotype isolates, the prevalence of PfRh2b full-
length and PfRh2b deletion was calculated as follows:
(number of PfRh2b allele isolates + (0.5 * number of mixed 
isolates))/total number of isolates [10]. The Chi square 
linear trends was used to determine if the differences in 
frequency over the years was statistically significant. Differ-
ences between groups were assessed using Mann–Whitney 
U-test. Wright’s fixation index (Fst) was also calculated to 
assess the extent of genetic differentiation of PfRh2b poly-
morphism in Thiès and Western Gambia over time.
Results
Evolution of the prevalence of PfRh2b deletion in fields 
isolates from Thiès and Western Gambia
In Thiès, the prevalence of the deletion decreased signifi-
cantly from 66.54% in 2007 to 38.1% in 2013 (P < 0.0001). 
This decline was not homogeneous with the presence 
of a peak in 2012, where PfRh2bdel form was present in 
43.62% of infections (Fig. 1a).
In Western Gambia, temporal variation in prevalence 
in PfRh2b deletion was observed between 1984 and 2013. 
The prevalence of PfRh2b deletion increased between 
1984 and 2005 from (58.04%) to (69.33%) (P = 0.03). 
From 2005 to 2007 there was a decline of the deletion to 
(47.47%) (P = 0.004). Between 2007 and 2012, the preva-
lence of this deletion increased significantly from 47.47 
to 83.02% (P = 0.00005) and finally declined significantly 
to 57.94% in 2013 (P = 0.001) (Fig.  1b). Since mixed 
Table 1 Allele frequencies used to calculate Fst according to years
Temporal differentiation of PfRh2b polymorphism in Thiès and Western Gambia populations. Fst value was calculated to assess the extent of temporal variation in the 
frequencies of PfRh2b alleles in both areas. The overall estimated value of Fst from 2007 to 2013 in Thiès was 0.09. In Western Gambia the Fst value from 1984 to 2013 
was 0.057
Fst, wright’s fixation index; h, gene diversity
Years THIES WESTERN GAMBIA
PfRh2bdel PfRh2bfull Gene diversity (h) PfRh2bdel PfRh2bfull Gene 
diversity 
(h)
1984 – – 0.58 0.42 0.487
2005 – – 0.69 0.31 0.428
2007 0.67 0.33 0.442 0.47 0.53 0.498
2008 0.65 0.35 0.455 0.66 0.34 0.449
2009 0.58 0.42 0.487 – – –
2010 0.39 0.61 0.372 0.73 0.27 0.394
2011 0.37 0.63 0.466 – – –
2012 0.44 0.56 0.493 0.83 0.17 0.282
2013 0.38 0.62 0.471 0.58 0.42 0.487
Average 0.497 0.503 0.455 0.648 0.351 0.432
Fst = 0.09 Fst = 0.057
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Table 2 Nucleotide sequence of haplotype clusters in Thiès
Haplotype cluster Molecular barcodes N (%) N (isolats) PfRh2bdel (%) PfRh2bfull (%)
Haplotype cluster 36 CAC TGC AGA CCG CAC CCA AGC CTG 0.345 2 100 0
Haplotype cluster 38 CAC TCG AGA TCG TCA CCA CGC TTG 0.345 2 0 100
Haplotype cluster 45 TAT TCC GGT CCG TCC CCT CGC TTG 0.345 2 100 0
Haplotype cluster 51 TAC TCC GGT TCG CAC ACA CGA CTG 0.345 2 100 0
Haplotype cluster 49 TAT TCG AAA TCG CAC CCT AGA TTG 0.345 2 100 0
Haplotype cluster 48 TAC TCC AGT CCA TAC ACA CGA TTG 0.345 2 100 0
Haplotype cluster 46 TAC TGC AGA TTG TAC CCA AAA CTG 0.345 2 50 50
Haplotype cluster 57 CAC TGC GGA TTG TAC CTA AGA CTG 0.345 2 50 50
Haplotype cluster 54 CGC TCC AGA CTA CAC CCT AAA CTG 0.345 2 0 100
Haplotype cluster 53 TAC TCC GGA TTG TCA CCA AGA CTG 0.345 2 100 0
Haplotype cluster 59 TAC TCC GGT TTA TAC CTT AGA CTG 0.345 2 0 100
Haplotype cluster 61 TAC CGG AGT CCG TAC CTA AGC CTG 0.345 2 0 100
Haplotype cluster 15 TAC TCC GGT TCG TAA ACT CGC CTG 0.345 2 50 50
Haplotype cluster 63 TAC TCC AGA CCG CCC CTA AAA TTG 0.345 2 0 100
Haplotype cluster 9 TAT TCC AGATXGCA ACT TCG ACT G 0.345 2 100 0
Haplotype cluster 62 TAC TCG AGA CTG CNCAT ACA CTTG 0.345 2 0 100
Haplotype cluster 13 TAC TCG AAACTXCCC ATA AGC TTG 0.345 2 0 100
Haplotype cluster 68 TAC CCC GGA CCA CCA ATA AGA CTG 0.345 2 0 100
Haplotype cluster 69 TAC TGG GAT CCG CAC CTA AGA CTG 0.345 2 0 100
Haplotype cluster 67 CAC TCC GGA TTG CCA CTT AGA TTG 0.345 2 50 50
Haplotype cluster 70 TAT TCC GGACXACA CAC TAG CTT G 0.345 2 0 100
Haplotype cluster 22 TAC TCC GGA TCG CAC CCT AGA TTG 0.345 2 50 50
Haplotype cluster 74 TAC TCC AGA CTA TCC ATT CGA TTG 0.345 2 50 50
Haplotype cluster 71 CAC TCG GGATTXCCA CTA AGC TTG 0.345 2 0 100
Haplotype cluster 80 CAT TCC AGTCCXCCA ATA AGA TTG 0.345 2 0 100
Haplotype cluster 72 TAT TGG GGA TCG CAA CCA AGA TTG 0.345 2 100 0
Haplotype cluster 77 TAC TGG AGT CCG TAC CTT AGC TTG 0.345 2 50 50
Haplotype cluster 97 CAC TCG AAATXATA CCT TAG CTT G 0.345 2 50 50
Haplotype cluster 87 TAC TCG GGT CTA TAA ATA AGA CTG 0.345 2 0 100
Haplotype cluster 89 TAC TCG AGT TTA TAC CTT AGA CTG 0.345 2 0 100
Haplotype cluster 92 TAT TGC AGTCCXCAA ATA AGC TTG 0.345 2 0 100
Haplotype cluster 84 CAC TCC AGT CCA CCACNTAG ATT G 0.345 2 100 0
Haplotype cluster 96 TAT TCC AGA CCG CAC ATT AGC CTG 0.345 2 50 50
Haplotype cluster 93 TAC TCC AGT CCG TCA CTT AGA CTG 0.345 2 100 0
Haplotype cluster 44 TAC TCC AGA CTA CAA CTA CGC CTG 0.345 2 0 100
Haplotype cluster 43 TAT TCC AGA TTG CAA CTT CGC CTG 0.517 3 100 0
Haplotype cluster 58 CAC TCG AGTTXACA ACC TAG CCT G 0.517 3 33 67
Haplotype cluster 7 CAC TCC GGA TTG CCA CTA AGA TTG 0.517 3 33 67
Haplotype cluster 19 TAT TCG AGT CTA CAC CTT CAC TTG 0.517 3 100 0
Haplotype cluster 21 TAC CCC GGT CCA CCA CTA AAA TTG 0.517 3 0 100
Haplotype cluster 23 CAC CCG AGT CCA CCA ACA AGA CTG 0.517 3 0 100
Haplotype cluster 95 CAC CCC GAATCXCAC CTA AGA CTG 0.517 3 0 100
Haplotype cluster 99 TAC TCC GAA CTG CAC ATT AGA TTG 0.517 3 100 0
Haplotype cluster 55 TAC TCC GGT TTG CAC ACA CGA CTG 0.69 4 100 0
Haplotype cluster 64 TAC TCG AGATXATA CAT ACA CTT G 0.69 4 0 100
Haplotype cluster 10 CAT TGC GAT CTG CAA CCT AAA CTG 0.69 4 100 0
Haplotype cluster 24 CAT TCC AGTCCXCCC ATT AGA TTG 0.69 4 25 75
Haplotype cluster 81 TAC TCC AGA TCG CAC CCA AGC CTG 0.69 4 75 25
Haplotype cluster 98 CAC TCG AGT TTA CAA CTA AGA TTG 0.69 4 25 75
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infections are uncommon in endemic populations, the 
frequency of infections with both deleted and full-length 
parasites (mixed) was determined. The result was highest 
in 2007 (0.10) and lowest in 2009 (0.02) in Thiès. In West-
ern Gambia, mixed infections were most common in the 
earliest population from 1984 (0.23) and lowest in 2008 
with (0.04) (Additional file 1: Table S1).
Overall, a significant decrease of the prevalence of 
PfRh2b deletion from 2007 to 2013 in Thiès (P < 0.0001) 
and fluctuating prevalence from 1984 to 2013 in Western 
Gambia were observed.
Prevalence of PfRh2b deletion according to age in Thiès 
and western Gambia
The presence of the deletion at high frequency in the gen-
eral population and the acquisition of antibodies in an age-
dependent manner against the c-terminal region of PfRh2b 
[10], have raised the interest to determine the prevalence 
of the deletion by age-group to see if the deletion would be 
more frequent in adults since they are long exposed. Thus, 
among the 1380 Plasmodium isolates assayed, 934 samples 
were available for age data and were analysed (651 from 
Thiès and 283 from Western Gambia). A median age was 
used to divide each population into two numerically equal 
groups.
In Thiès, since the study population mainly consists 
of adults (62%), the median age of the 651 patients was 
18 years. Thus, the PfRh2b deletion form was less com-
mon in children compared to older patients (Fig.  2a). 
Using the Mann–Whitney U-test, a significant difference 
in the presence of PfRh2b deletion was found (P = 0.037), 
suggesting that there is an association between age and 
the presence of this deletion in Thiès.
In contrast, in Western Gambia, the population study is 
consisting of children (under 16 years of age); the median 
age of the 283 patients was 5 years. The PfRh2b deletion 
was more common in younger children compared to 
older children (Fig. 2b), but the difference is not signifi-
cant by the Mann–Whitney U-test (P = 0.316).
Temporal differentiation of PfRh2b polymorphisms 
in Senegal and Gambia populations
Genetic diversity of the genes in natural parasites popula-
tions is a real obstacle for the validation of potential vac-
cine candidate. In this study, the degree of divergence to 
which PfRh2b gene is subject to selection was estimated 
by calculating Fst from the allelic frequencies of this 
locus according to years.
In Senegal the Fst value obtained from 2007 to 2013 
was high (0.09), suggesting high degree of allelic diver-
gence in this region over the time. In contrast, the Fst 
value obtained in The Gambia from 1984 to 2013 was low 
(0.057), suggesting less genetic differentiation of these 
alleles in this area over the time (Table 1).
Prevalence of PfRh2b in isolates grouped by molecular 
barcode
It has been observed by barcoding in Thiès that the 
parasite, having undergone various interventions and 
pressures, has adapted by evolving towards to a type of 
parasite [28]. It is also assumed that parasite, initially 
having the PfRh2b full-length, has adapted by presenting 
the deletion following the different pressures. To test the 
hypothesis that the parasite with PfRh2b deletion may be 
linked by specific cluster, the prevalence of PfRh2b dele-
tion according to molecular barcode was determined. 
Table 2 (continued)
Haplotype cluster Molecular barcodes N (%) N (isolats) PfRh2bdel (%) PfRh2bfull (%)
Haplotype cluster 5 TAC TCG AAA CTG CCC ATA AGC TTG 0.69 4 0 100
Haplotype cluster 65 CAC TCC AAA TCG TAC CTT AGA TTG 0.862 5 100 0
Haplotype cluster 8 TAC CCC GGT CCA CAC CTT AAC TTG 0.862 5 100 0
Haplotype cluster 11 TAC TCG AGA TCA TAC ATA CAC TTG 0.862 5 0 100
Haplotype cluster 12 CAC TGC GAT CTG CAA CCT AAA CTG 0.862 5 100 0
Haplotype cluster 6 CAT TCC AGT CCG CCA ATA AGA TTG 1.034 6 0 100
Haplotype cluster 26 CAC TCC AGT CCG TCA CCA AGA TTG 1.034 6 17 83
Haplotype cluster 17 TAC CCC GGT CCA CCA ATA AGA TTG 1.207 7 0 100
Haplotype cluster 16 TAC TCC AGA TTA CAA CCT AGC CTG 1.207 7 100 0
Haplotype cluster 66 TGT TCC AGT TTA TCA CCA CGC CTG 1.379 8 12.50 87.50
Haplotype cluster 18 TAT TCC AGT CCA CCC ATA AGA CTG 1.552 9 89 11
Haplotype cluster 4 TAC TCC GGTTXGCA CAC ACG ACT G 2.586 15 100 0
Haplotype cluster 29 TAC CCC GGT CCA CCA ATA AGA CTG 7.241 42 9.50 90.50
UNIQUES 58.27 338 49.11 50.89
N, number of isolates; PfRh2bdel, deletion present; PfRh2bfull, full-length sequence
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Among the samples that were analysed for PfRh2b poly-
morphism, 580 from Thiès had been previously geno-
typed using the 24-SNP barcode [33] and the results were 
classified into two groups: a group named “cluster” which 
includes the samples having similarities with at least one 
other isolate in their nucleotide sequences and a group 
called “unique” grouping parasites with unique SNP 
barcode. 41.73% (242/580) of samples belonged to the 
cluster-group and 58.27% (338/580) were in the unique 
group (Table 2).
No significant difference in the frequency of PfRh2b 
deletion between the cluster-group and the unique group 
was found (P = 0.5014). Among the 338 isolates having 
unique barcodes, 166 (49.11%) had the deletion and 172 
(50.89%) had the full-length fragment of PfRh2b gene. 
Therefore, both alleles PfRh2b deletion and PfRh2b full-
length, had a similar distribution within the unique geno-
type group. Furthermore, all the 242 isolates belonging to 
the cluster-group were also tested to assess the frequency 
of PfRh2b alleles. In this group, 62 distinct subgroups 
were identified. The results showed that 20 haplotype 
clusters had only the deletion variant of PfRh2b gene, 
24 subgroups had only the full-length fragment and the 
remaining 18 subgroups were parasites having the dele-
tion and full-length (Table 2).
The number of samples is differently distributed in 
each of the 20 haplotype clusters with the deletion, and 
this distribution varies also over time (Table  3). Evolu-
tion over time of the 20 haplotype clusters containing 
only the PfRh2b deletion shows a decrease of the preva-
lence between 2008 and 2010 as well as a slight increase 
between 2010 and 2013 (Fig. 3). Since the numbers in the 
majority of the cluster group with the PfRh2b deletion 
are limited, haplotypes with n > 5 were examined further 
(haplotype 4 and 16) (Fig. 4). Haplotype cluster 4 with the 
deletion was found in 2008 (n = 12) and 2009 (n = 3), but 
not in the other years. Meanwhile, haplotype cluster 16 
with the deletion was present in 2011 (n = 1), and 2012 
(n = 6), but not in the other years (Fig.  5). The analysis 
of the results over time suggests that the frequency of 
PfRh2b deletion is related to the presence of some haplo-
type clusters in this population.   
Table 3 Frequency of  the  deletion over  time within  each 
cluster that contain only the deletion
Haplotype Samples ID Molecular barcodes Samples ID Del Full
Cluster 65 Th 007.2010 CACTCCAAATCGTACCTTAGATTG Th 007.2010 1 0
Th 015.2010 CACTCCAAATCGTACCTTAGATTG Th 015.2010 1 0
Th 107.2010 CACTCCAAATCGTACCTTAGATTG Th 107.2010 1 0
Th 123.2010 CACTCCAAATCGTACCTTAGATTG Th 123.2010 1 0
Th 135.2010 CACTCCAAATCGTACCTTAGATTG Th 135.2010 1 0
Cluster 84 Th 125.2013 CACTCCAGTCCACCACNTAGATTG Th 125.2013 1 0
Th 127.2013 CACTCCAGTCCACCACNTAGATTG Th 127.2013 1 0
Cluster 12 Th 007.2011 CACTGCGATCTGCAACCTAAACTG Th 007.2011 1 0
Th 010.2011 CACTGCGATCTGCAACCTAAACTG Th 010.2011 1 0
Th 061.2011 CACTGCGATCTGCAACCTAAACTG Th 061.2011 1 0
Th 055.2012 CACTGCGATCTGCAACCTAAACTG Th 055.2012 1 0
Th 222.2012 CACTGCGATCTGCAACCTAAACTG Th 222.2012 1 0
Cluster 10 Th 124.2010 CATTGCGATCTGCAACCTAAACTG Th 124.2010 1 0
Th 027.2011 CATTGCGATCTGCAACCTAAACTG Th 027.2011 1 0
Th 028.2011 CATTGCGATCTGCAACCTAAACTG Th 028.2011 1 0
Th 116.2011 CATTGCGATCTGCAACCTAAACTG Th 116.2011 1 0
Cluster 8 Th 038.2010 TACCCCGGTCCACACCTTAACTTG Th 038.2010 1 0
Th 076.2010 TACCCCGGTCCACACCTTAACTTG Th 076.2010 1 0
Th 179.2010 TACCCCGGTCCACACCTTAACTTG Th 179.2010 1 0
Th 011.2011 TACCCCGGTCCACACCTTAACTTG Th 011.2011 1 0
Th 073.2011 TACCCCGGTCCACACCTTAACTTG Th 073.2011 1 0
Cluster 16 Th 099.2011 TACTCCAGATTACAACCTAGCCTG Th 099.2011 1 0
Th 038.2012 TACTCCAGATTACAACCTAGCCTG Th 038.2012 1 0
Th 043.2012 TACTCCAGATTACAACCTAGCCTG Th 043.2012 1 0
Th 061.2012 TACTCCAGATTACAACCTAGCCTG Th 061.2012 1 0
Th 098.2012 TACTCCAGATTACAACCTAGCCTG Th 098.2012 1 0
Th 123.2012 TACTCCAGATTACAACCTAGCCTG Th 123.2012 1 0
Th 160.2012 TACTCCAGATTACAACCTAGCCTG Th 160.2012 1 0
Cluster 48 Th 131.2008 TACTCCAGTCCATACACACGATTG Th 131.2008 1 0
Th 148.2008 TACTCCAGTCCATACACACGATTG Th 148.2008 1 0
Cluster 93 Th 151.2013 TACTCCAGTCCGTCACTTAGACTG Th 151.2013 1 0
Th 154.2013 TACTCCAGTCCGTCACTTAGACTG Th 154.2013 1 0
Cluster 99 Th 173.2013 TACTCCGAACTGCACATTAGATTG Th 173.2013 1 0
Th 191.2013 TACTCCGAACTGCACATTAGATTG Th 191.2013 1 0
Th 213.2013 TACTCCGAACTGCACATTAGATTG Th 213.2013 1 0
Cluster 53 Th 145.2009 TACTCCGGATTGTCACCAAGACTG Th 145.2009 1 0
Th 150.2009 TACTCCGGATTGTCACCAAGACTG Th 150.2009 1 0
Cluster 51 Th 042.2008 TACTCCGGTTCGCACACACGACTG Th 042.2008 1 0
Th 073.2008 TACTCCGGTTCGCACACACGACTG Th 073.2008 1 0
Cluster 55 Th 044.2008 TACTCCGGTTTGCACACACGACTG Th 044.2008 1 0
Th 101.2008 TACTCCGGTTTGCACACACGACTG Th 101.2008 1 0
Th 105.2008 TACTCCGGTTTGCACACACGACTG Th 105.2008 1 0
Th 250.2008 TACTCCGGTTTGCACACACGACTG Th 250.2008 1 0
Cluster 4 Th 004.2008 TACTCCGGTTXGCACACACGACTG Th 004.2008 1 0
Th 014.2008 TACTCCGGTTXGCACACACGACTG Th 014.2008 1 0
Th 036.2008 TACTCCGGTTXGCACACACGACTG Th 036.2008 1 0
Th 068.2008 TACTCCGGTTXGCACACACGACTG Th 068.2008 1 0
Th 088.2008 TACTCCGGTTXGCACACACGACTG Th 088.2008 1 0
Th 095.2008 TACTCCGGTTXGCACACACGACTG Th 095.2008 1 0
Th 112.2008 TACTCCGGTTXGCACACACGACTG Th 112.2008 1 0
Th 120.2008 TACTCCGGTTXGCACACACGACTG Th 120.2008 1 0
Th 173.2008 TACTCCGGTTXGCACACACGACTG Th 173.2008 1 0
Th 188.2008 TACTCCGGTTXGCACACACGACTG Th 188.2008 1 0
Th 214.2008 TACTCCGGTTXGCACACACGACTG Th 214.2008 1 0
Th 228.2008 TACTCCGGTTXGCACACACGACTG Th 228.2008 1 0
Th 108.2009 TACTCCGGTTXGCACACACGACTG Th 108.2009 1 0
Th 109.2009 TACTCCGGTTXGCACACACGACTG Th 109.2009 1 0
Th 153.2009 TACTCCGGTTXGCACACACGACTG Th 153.2009 1 0
Cluster 43 Th 143.2007 TATTCCAGATTGCAACTTCGCCTG Th 143.2007 1 0
Th 145.2007 TATTCCAGATTGCAACTTCGCCTG Th 145.2007 1 0
Th 155.2007 TATTCCAGATTGCAACTTCGCCTG Th 155.2007 1 0
Cluster 9 Th 108.2010 TATTCCAGATXGCAACTTCGACTG Th 108.2010 1 0
Th 149.2010 TATTCCAGATXGCAACTTCGACTG Th 149.2010 1 0
Cluster 45 Th 001.2008 TATTCCGGTCCGTCCCCTCGCTTG Th 001.2008 1 0
Th 003.2008 TATTCCGGTCCGTCCCCTCGCTTG Th 003.2008 1 0
Cluster 49 Th 070.2008 TATTCGAAATCGCACCCTAGATTG Th 070.2008 1 0
Th 090.2008 TATTCGAAATCGCACCCTAGATTG Th 090.2008 1 0
Cluster 72 Th 075.2012 TATTGGGGATCGCAACCAAGATTG Th 075.2012 1 0
Th 152.2012 TATTGGGGATCGCAACCAAGATTG Th 152.2012 1 0
Cluster 36 Th 001.2007 CACTGCAGACCGCACCCAAGCCTG Th 001.2007 1 0
Th 011.2007 CACTGCAGACCGCACCCAAGCCTG Th 011.2007 1 0
Cluster 19 Th 121.2011 TATTCGAGTCTACACCTTCACTTG Th 121.2011 1 0
Th 140.2011 TATTCGAGTCTACACCTTCACTTG Th 140.2011 1 0
Th 175.2012 TATTCGAGTCTACACCTTCACTTG Th 175.2012 1 0
Fig. 3 Evolution over time of PfRh2b deletion in haplotype clusters 
having only the deletion in Thiès
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Discussion
Plasmodium falciparum reticulocyte binding protein 
homolog 2b (PfRh2b), has been reported to present a 
large structural polymorphism (0.58  kb deletion) in the 
c-terminal region. It is an important target of immunity 
[10] and could be considered as a potential candidate 
for blood stage vaccine development. Previous works 
showed that PfRh2b deletion was highly prevalent in iso-
lates from Senegal and Africa [10, 26, 27] and present in 
different populations of the world [10]. However, malaria 
prevalence has been declining and interventions are tak-
ing place across sub-Saharan Africa. As these may be 
selecting for parasite subtypes, the changes imposed on 
this PfRh2b protein remains unknown. Therefore, the 
goal of this study was to follow the temporal evolution 
of the prevalence of PfRh2b deletion using samples from 
2007 to 2013 in Thiès and from 1984 to 2013 in Western 
Gambia.
For the two populations, the prevalence of the deletion 
variant of PfRh2b ranged from 30 to 80%. However, while 
the prevalence of this deletion declined in Senegal, there 
was a steady increase in the Gambian populations stud-
ied until 2012. The differences in the trends between the 
two countries and within each country can be the result 
in random shifts in parasite allele frequencies in differ-
ent geographic region due to genetic drift in isolated 
populations. Other explanations could be the genetic 
background of the host, the environmental modification, 
immune pressure, drug pressure and or drug resistance 
[28, 34].
Furthermore, the prevalence of PfRh2b deletion in dif-
ferent age groups in Thiès showed that the deletion was 
Fig. 4 Percentage of isolates of cluster‑group and unique based on PfRh2b polymorphism in Thiès. Scheme showing the association between 
the polymorphism of PfRh2b gene and specific barcode of parasite. “Haplotype clusters” which had n = 4 samples were represented. Haplotype 
cluster 55; 10; 65; 8; 12; 16 and 4 had only the deletion of PfRh2b gene (Blue pie chart); Haplotype cluster 64; 5; 11; 6 and 17 had only the full‑length 
fragment (orange pie chart). The remaining (Haplotype cluster 24; 31; 98; 26; 66; 18 and 29) were parasites having deletion and full‑length alleles. 
The last pie chart (with n = 338) represented the parasites with unique barcode. Del, deletion; Full, full‑length sequence; n, number of isolates
(See figure on next page.)
Fig. 5 Frequency of deletion by year in haplotype clusters 4 and 16. Monitoring of the population frequency and PfRh2b alleles frequencies of 
haplotype cluster 4 and 16 over the time. a Haplotype cluster 4 was found in 2008 (n = 12) and 2009 (n = 3), but not in the other years. b Haplotype 
cluster 16 was present in 2011 (n = 1) and 2012 (n = 6), but not in the other years. Del, deletion; Full, full‑length sequence; n, number of isolates
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significantly less present in children compared to older 
patients. In Western Gambia, the prevalence of PfRh2b 
deletion was more common in younger children com-
pared to older children, but the difference is not signifi-
cant. With those results observed in these two sites, the 
association between age and deletion is not clear. How-
ever, a previous study did not find a relation between age 
and deletion [10].
Moreover, the evaluation of temporal variation of 
PfRh2b polymorphism in Senegal and Gambia popula-
tions was performed by using Fst to estimate the degree 
by which this locus is subject to a selection. Indeed, 
selection intensity can lead to differences in diversity and 
generate divergence among natural populations.
Thus, the Fst value (0.09) in Thiès, from 2007 to 2013 is 
higher than those observed for PfRh2b, Msp2, EBA 175 
and Pfs48/45 within Senegal and between African coun-
tries [10]. However, this Fst value was lower than those 
observed for Msp2 and EBA 175 dimorphisms, which 
has been reported to exhibit less genetic differentiation 
and possible balancing selection in the global popula-
tions (African, South East Asian and Latin American 
populations) [10]. In Western Gambia, the Fst value was 
low and similar to that observed for the EBA 175 dimor-
phism within Senegal, which has been shown to have also 
minimal genetic differentiation globally [10]. Overall, 
the Fst values obtained in this study indicate less genetic 
differentiation suggesting that PfRh2b polymorphism is 
under balancing selection over time in Thiès and Western 
Gambia.
Additionally, the prevalence of PfRh2b deletion accord-
ing to the molecular barcode of isolates from Thiès was 
analysed to determine whether the deletion is associ-
ated with a specific barcode in this region. Analysis of the 
distribution of PfRh2b polymorphism in shared barcode 
clusters suggests that deletion is associated at some hap-
lotype clusters in the population. However, the removal 
of large clusters from the population do not effect the 
prevalence of the deletion over time. The results of the 
study provide information on the genetic diversity of the 
PfRh2b gene that could be useful in the validation of this 
antigen as a potential vaccine candidate.
Conclusion
Temporal trends in the frequency of the deleted PfRh2b 
variant differed in Senegal and The Gambia. This may 
suggest an effect of local factors on the prevalence of 
PfRh2b deletion between the years. Changes in the fre-
quency of PfRh2b polymorphism over the time could 
be an obstacle to the implementation of this protein as 
a potential vaccine candidate as allele specific immunity 
may affect its efficacy. It will be important to investigate 
the natural antibodies responses against PfRh2b over the 
time in different malaria endemic countries to evaluate 
this antigen as a vaccine candidate.
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